Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
1.52 EUR
151.89 M EUR
2.19 B EUR
188.17 M
About BioMarin Pharmaceutical Inc.
Sector
Industry
CEO
Alexander Hardy
Website
Headquarters
San Rafael
Founded
1997
FIGI
BBG000DB0R28
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
BMRN5187965
BioMarin Pharmaceutical Inc. 1.25% 15-MAY-2027Yield to maturity
4.07%
Maturity date
May 15, 2027
Explore more bonds
Curated watchlists where BM8 is featured.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange BIOMARIN PHAR. DL-,001 stocks are traded under the ticker BM8.
We've gathered analysts' opinions on BIOMARIN PHAR. DL-,001 future price: according to them, BM8 price has a max estimate of 120.25 EUR and a min estimate of 61.54 EUR. Watch BM8 chart and read a more detailed BIOMARIN PHAR. DL-,001 stock forecast: see what analysts think of BIOMARIN PHAR. DL-,001 and suggest that you do with its stocks.
Yes, you can track BIOMARIN PHAR. DL-,001 financials in yearly and quarterly reports right on TradingView.
BIOMARIN PHAR. DL-,001 is going to release the next earnings report on Feb 20, 2025. Keep track of upcoming events with our Earnings Calendar.
BM8 earnings for the last quarter are 0.49 EUR per share, whereas the estimation was 0.48 EUR resulting in a 3.59% surprise. The estimated earnings for the next quarter are 0.52 EUR per share. See more details about BIOMARIN PHAR. DL-,001 earnings.
BIOMARIN PHAR. DL-,001 revenue for the last quarter amounts to 669.78 M EUR, despite the estimated figure of 631.78 M EUR. In the next quarter, revenue is expected to reach 675.31 M EUR.
BM8 net income for the last quarter is 95.27 M EUR, while the quarter before that showed 100.06 M EUR of net income which accounts for −4.78% change. Track more BIOMARIN PHAR. DL-,001 financial stats to get the full picture.
No, BM8 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 14, 2024, the company has 3.40 K employees. See our rating of the largest employees — is BIOMARIN PHAR. DL-,001 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BIOMARIN PHAR. DL-,001 EBITDA is 440.48 M EUR, and current EBITDA margin is 12.35%. See more stats in BIOMARIN PHAR. DL-,001 financial statements.
Like other stocks, BM8 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BIOMARIN PHAR. DL-,001 stock right from TradingView charts — choose your broker and connect to your account.